InSilico Medicine Cayman TopCo valuation
$30.60Change from previous close: −8.55%Absolute change: −$2.86
Valuation
The average price target of 10 analysts is $76.70.
Data as of November 21, 2026
InSilico Medicine Cayman TopCo compared with similar companies
InSilico Medicine Cayman TopCo's Forward P/E: 19.9, −45% against the median of a group of 9 similar companies (36.1).
| Metric | InSilico Medicine Cayman TopCo | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| Forward P/E | 19.9 | 36.1 | 26.0 – 45.4 | Low |
| Price/book | 4.64 | 4.64 | 2.59 – 7.27 | Middle |
| Price/sales | 150.3 | 18.4 | 7.40 – 43.6 | High |
| Gross margin | 87.9% | 77.3% | 49.8% – 84.4% | High |
| Operating margin | -6.9% | 14.0% | -18.8% – 20.5% | Middle |
| Net margin | -220.3% | 3.8% | -61.6% – 25.3% | Low |
| ROE | 443.1% | 10.4% | -1.8% – 35.7% | High |
| Debt/equity | 0.04 | 0.16 | 0.05 – 0.41 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $20.31B
- Enterprise value
- $19.37B
- P/E (trailing 12 months)
- -6.48
- PEG
- 1.06
- EV/EBITDA
- -3,038.0
- EV/revenue
- 143.4
Profitability and growth
- ROA
- -1.4%
- ROIC
- 10.9%
- Revenue growth (year over year)
- 287.2%
- Earnings growth (year over year)
- -124.0%
Financial health
- Total cash
- $584.82M
- Total debt
- $19.66M
- Current ratio
- 8.71
- Quick ratio
- 8.65
- Altman Z-Score
- 32.0
- Piotroski F-Score
- 4.00
Dividends
- Dividend yield
- 0.0%
Analysts and estimates
- Average price target
- $76.70
- Median price target
- $76.99
- High price target
- $100.02
- Low price target
- $50.01
- Analysts with a price target
- 10
- Consensus
- Strong buy
- Forward EPS
- $1.74
- EPS estimate, current year
- $0.14
Shares and trading
- Average volume
- 14.15M
- Shares outstanding
- 586.56M
- Float
- 502.94M
- Institutional ownership
- 31.2%
- Insider ownership
- 7.8%
